Aditxt, Inc. (ADTX)
| Market Cap | 8.28M |
| Revenue (ttm) | 749,475 |
| Net Income (ttm) | -29.73M |
| Shares Out | 1.25M |
| EPS (ttm) | -13.17 |
| PE Ratio | n/a |
| Forward PE | 0.37 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,697,418 |
| Open | 6.52 |
| Previous Close | 4.82 |
| Day's Range | 5.88 - 8.47 |
| 52-Week Range | 3.27 - 76.40 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 61.00 (+820.06%) |
| Earnings Date | Nov 14, 2023 |
About ADTX
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. It is also developing ADi products for organ trans... [Read more]
Financial Performance
In 2022, Aditxt's revenue was $933,715, an increase of 788.96% compared to the previous year's $105,034. Losses were -$27.61 million, -40.32% less than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ADTX stock is "Strong Buy" and the 12-month stock price forecast is $61.0.
News
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Bioscienc...
Aditxt (ADTX) stock price just soared but gains could be brief
The Aditxt (NASDAQ: ADTX) stock price jumped by more than 83% on Tuesday, making it one of the best performers in Wall Street. The shares surged to a high of $9.47, its highest point since October 19t...
ADTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aditxt, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aditxt, Inc. (NASDAQ: ADTX) and Evofem Biosciences, Inc. is fair to Aditxt shareholders...
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
RICHMOND, Va. & SAN DIEGO--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evo...
Aditxt, Inc. to Present at 8th Annual Dawson James Conference
Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2...
Aditxt, Inc. Announces Appointment of Ernie Lee as CEO of its Wholly-Owned Subsidiary, Pearsanta, to Lead Launch of Test2Treat.me Platform
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation activation company focused on the discovery, development, and deployment of techno...
Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
RICHMOND, Va. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing ...
Aditxt Announces Closing of $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...
Aditxt stock price has plummeted: avoid at all cost
Aditxt (NASDAQ: ADTX) stock price has been in the spotlight in the past few days. The shares plunged by more than 24% on Friday, one of its worst days this year.
Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the...
Aditxt, Inc. (NASDAQ: ADTX) Provides Shareholder Update and Planned Strategy for Achieving Commercial Scale
RICHMOND, Va.--(BUSINESS WIRE)-- #autoimmunity--Aditxt®, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on innovation and activation of precision medicine therape...
CORRECTING and REPLACING Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
RICHMOND, Va.--(BUSINESS WIRE)--First paragraph, first sentence of release should read: Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and ...
Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on August 18, 2023
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system...
Aditxt, Inc.'s Wholly-Owned Subsidiary Pearsanta, Inc. Looks to Expand Customer Base, Payor Access, and Genetic Testing with a Non-Binding Letter of Intent to Acquire Natural State Laboratories and Natural State Genomics
RICHMOND, Va.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate...
Aditxt Subsidiary Adimune Signs Clinical Trial Agreement with Top Research Institution to Study Stiff Person Syndrome
RICHMOND, Va.--(BUSINESS WIRE)-- #StiffPersonSyndrome--Aditxt®, Inc. announces that its subsidiary Adimune,™ Inc. has signed a clinical trial agreement with Mayo Clinic to study Stiff Person Syndrome.
Aditxt Announces Closing of $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...
Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the...
Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid – with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt,® Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune syst...
Aditxt Issues Shareholder Update
RICHMOND, Va--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on therapeutics and technologies that monitor and modulate ...
Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...
Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...
Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore™ Program and Appoints Healthcare Executive and Current Head of AditxtScore™ Anthony Voorhies to Serve as its President
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc., (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation company developing and commercializing technologies with a focus on monitoring and modulating th...
Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modul...
